GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » Loans Receivable

Orthocell (ASX:OCC) Loans Receivable : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Orthocell Loans Receivable?

Orthocell's Loans Receivable for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Orthocell Loans Receivable Historical Data

The historical data trend for Orthocell's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthocell Loans Receivable Chart

Orthocell Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orthocell Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Orthocell Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Orthocell Loans Receivable Related Terms

Thank you for viewing the detailed overview of Orthocell's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Orthocell (ASX:OCC) Business Description

Traded in Other Exchanges
N/A
Address
90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.